Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia

Chest

Volumn 155, Issue 4, 2019, Pages 795-804

  Ceccato, Adrian ^a   Cilloniz, Catia ^a   Martin Loeches, Ignacio ^b   Ranzani, Otavio T ^a,c   Gabarrus, Albert ^a   Bueno, Leticia ^a   Garcia Vidal, Carolina ^a   Ferrer, Miquel ^a   Niederman, Michael S ^d   Torres, Antoni ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b ST JAMES S HOSPITAL   (Ireland)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

community acquired pneumonia; inflammatory response; macrolide; sepsis; Streptococcus pneumoniae

Indexed keywords

AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; BETA LACTAM;

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NONINVASIVE VENTILATION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SPAIN; STREPTOCOCCUS PNEUMONIAE; CAUSE OF DEATH; COMMUNITY ACQUIRED INFECTION; EPIDEMIOLOGY; FOLLOW UP; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PROPENSITY SCORE; SPUTUM; STREPTOCOCCUS PNEUMONIA; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CAUSE OF DEATH; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LENGTH OF STAY; MACROLIDES; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; PROPENSITY SCORE; PROSPECTIVE STUDIES; SPAIN; SPUTUM; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE;

EID: 85061941481     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2018.11.006     Document Type: Article

References (50)

1. Prina, E., Ranzani, O.T., Torres, A., Community-acquired pneumonia. Lancet 386:9998 (2015), 1097–1108.
2. Shindo, Y., Ito, R., Kobayashi, D., et al. Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study. Lancet Infect Dis 15:9 (2015), 1055–1065.
3. Mandell, L.A., Wunderink, R.G., Anzueto, A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44:suppl 2 (2007), S27–S72.
4. National Institute for Health and Care Excellence. Pneumonia in adults: diagnosis and management. Clinical guideline CD191. Published December 2014. Accessed April 5, 2018 https://www.nice.org.uk/guidance/cg191/chapter/1-Recommendations#community-acquired-pneumonia-2.
5. Woodhead, M., Blasi, F., Ewig, S., et al. Guidelines for the management of adult lower respiratory tract infections: full version. Clin Microbiol Infect 17:suppl 6 (2011), E1–E59.
6. Postma, D.F., van Werkhoven, C.H., van Elden, L.J.R., et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 372:14 (2015), 1312–1323.
7. Garin, N., Genné D., Carballo, S., et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 174:12 (2014), 1894–1901.
8. Asadi, L., Sligl, W.I., Eurich, D.T., et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 55:3 (2012), 371–380.
9. Mortensen, E.M., Halm, E.A., Pugh, M.J., et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 311:21 (2014), 2199–2208.
10. Martin-Loeches, I., Lisboa, T., Rodriguez, A., et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 36:4 (2010), 612–620.
11. Lee, J.S., Giesler, D.L., Gellad, W.F., Fine, M.J., Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. JAMA 315:6 (2016), 593–602.
12. Rodrigo, C., Mckeever, T.M., Woodhead, M., Lim, W.S., British Thoracic Society. Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia. Thorax 68:5 (2013), 493–495.
13. De la Calle, C., Ternavasio-de la Vega, H.G., Morata, L., et al. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: a propensity score analysis. J Infect 76:4 (2018), 342–347.
14. Nie, W., Li, B., Xiu, Q., β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. J Antimicrob Chemother 69:6 (2014), 1441–1446.
15. Paul, M., Nielsen, A.D., Gafter-Gvili, A., et al. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis. Eur Respir J 30:3 (2007), 525–531.
16. Restrepo, M.I., Mortensen, E.M., Waterer, G.W., Wunderink, R.G., Coalson, J.J., Anzueto, A., Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 33:1 (2009), 153–159.
17. Pereira, J.M., Gonçalves-Pereira, J., Ribeiro, O., Baptista, J.P., Froes, F., Paiva, J.A., Impact of antibiotic therapy in severe community-acquired pneumonia: data from the INFAUCI study. J Crit Care 43 (2018), 183–189.
18. Giamarellos-Bourboulis, E.J., Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 31:1 (2008), 12–20.
19. Kovaleva, A., Remmelts, H.H.F., Rijkers, G.T., Hoepelman, A.I.M., Biesma, D.H., Oosterheert, J.J., Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review. J Antimicrob Chemother 67:3 (2012), 530–540.
20. Dalhoff, A., Shalit, I., Immunomodulatory effects of quinolones. Lancet Infect Dis 3:6 (2003), 359–371.
21. Menéndez, R., Sahuquillo-Arce, J.M., Reyes, S., et al. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest 141:6 (2012), 1537–1545.
22. Baddour, L.M., Yu, V.L., Klugman, K.P., et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 170:4 (2004), 440–444.
23. Martínez, J.A., Horcajada, J.P., Almela, M., et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 36:4 (2003), 389–395.
24. Waterer, G.W., Somes, G.W., Wunderink, R.G., Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161:15 (2001), 1837–1842.
25. Fine, M.J., Auble, T.E., Yealy, D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:4 (1997), 243–250.
26. Vincent, J.L., Moreno, R., Takala, J., et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: on behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:7 (1996), 707–710.
27. Lim, W.S., Eerden, MM van der, Laing, R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58:5 (2003), 377–382.
28. Torres, A., Sibila, O., Ferrer, M., et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 313:7 (2015), 677–686.
29. Hosmer, D., Lemeshow, S., Applied Logistic Regression. 1989, Wiley, New York.
30. Healey, J.F., Statistics: A Tool for Social Research. 9th ed., 2011, Wadsworth, Belmont, CA.
31. Joffe, M.M., Rosenbaum, P.R., Invited commentary: propensity scores. Am J Epidemiol 150:4 (1999), 327–333.
32. Brookhart, M.A., Schneeweiss, S., Rothman, K.J., Glynn, R.J., Avorn, J., Stürmer, T., Variable selection for propensity score models. Am J Epidemiol 163:12 (2006), 1149–1156.
33. Sterne, J.A.C., White, I.R., Carlin, J.B., et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ, 338, 2009, b2393.
34. Arnold, F.W., Lopardo, G., Wiemken, T.L., et al. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. Respir Med 140 (2018), 115–121.
35. Ceccato, A., Torres, A., Cilloniz, C., et al. Invasive disease vs urinary antigen-confirmed pneumococcal community-acquired pneumonia. Chest 151:6 (2017), 1311–1319.
36. Vardakas, K.Z., Trigkidis, K.K., Falagas, M.E., Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect 23:4 (2017), 234–241.
37. Zhang, Y.-Q., Zou, S.-L., Zhao, H., Zhang, M.-M., Han, C.-L., Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community-acquired pneumonia: a meta-analysis. Am J Emerg Med 36:10 (2018), 1759–1765.
38. Okumura, J., Shindo, Y., Takahashi, K., et al. Central Japan Lung Study Group. Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: impact of β-lactam plus macrolide combination therapy. Respirology 23:5 (2018), 526–534.
39. Chalmers, J.D., Singanayagam, A., Hill, A.T., C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 121:3 (2008), 219–225.
40. Menéndez, R., Cavalcanti, M., Reyes, S., et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 63:5 (2008), 447–452.
41. Póvoa, P., Teixeira-Pinto, A.M., Carneiro, A.H., Portuguese Community-Acquired Sepsis Study Group (SACiUCI). C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-center prospective observational study. Crit Care, 15(4), 2011, R169.
42. Welte, T., Dellinger, R.P., Ebelt, H., et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med 44:4 (2018), 438–448.
43. Dela Cruz, C.S., Wunderink, R.G., Christiani, D.C., et al. Future research directions in pneumonia: NHLBI Working Group Report. Am J Respir Crit Care Med 15:198 (2018), 256–263.
44. Dalhoff, A., Immunomodulatory activities of fluoroquinolones. Infection 33:suppl 2 (2005), 55–70.
45. Prina, E., Ceccato, A., Torres, A., New aspects in the management of pneumonia. Crit Care, 20(1), 2016, 267.
46. Pasquale, T.R., Tan, J.S., Nonantimicrobial effects of antibacterial agents. Clin Infect Dis 40:1 (2005), 127–135.
47. Lagrou, K., Peetermans, W.E., Jorissen, M., Verhaegen, J., Van Damme, J., Van Eldere, J., Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory epithelial cells in vitro. J Antimicrob Chemother 46:5 (2000), 717–723.
48. Anderson, R., Feldman, C., Pneumolysin as a potential therapeutic target in severe pneumococcal disease. J Infect 74:6 (2017), 527–544.
49. Anderson, R., Steel, H.C., Cockeran, R., et al. Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae. J Antimicrob Chemother 59:2 (2007), 224–229.
50. Jain, S., Self, W.H., Wunderink, R.G., et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 373:5 (2015), 415–427.